Botanical Drug CMC Requirements Should Track OTC Monographs - AHPA
This article was originally published in The Tan Sheet
Executive Summary
Chemistry, manufacturing and controls (CMC) information should not be a prerequisite for botanical OTCs if it is not required for non-botanical OTC drugs, the American Herbal Products Association says.
You may also be interested in...
FDA Botanical Drug Products Final Guidance Stresses Batch Consistency
An FDA final guidance on botanical drug products includes new language recommending that firms demonstrate "batch-to-batch consistency" for botanical drug candidates through the clinical development process prior to submitting an NDA
FDA Botanical Drug Products Final Guidance Stresses Batch Consistency
An FDA final guidance on botanical drug products includes new language recommending that firms demonstrate "batch-to-batch consistency" for botanical drug candidates through the clinical development process prior to submitting an NDA
FDA Botanical Drug Products Final Guidance Stresses Batch Consistency
An FDA final guidance on botanical drug products includes new language recommending that firms demonstrate "batch-to-batch consistency" for botanical drug candidates through the clinical development process prior to submitting an NDA